Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer.

Overview of attention for article published in Annals of Surgery, August 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 6 news outlets

twitter: 1 X user

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 6 news stories from 6 outlets.

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

BioSpace, 08 Jan 2026

10 min read – STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to…

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

Times Argus, 07 Jan 2026

Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today…

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

Stockwatch, 07 Jan 2026

– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response…

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

MarketScreener, 07 Jan 2026

Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.